298 related articles for article (PubMed ID: 35287555)
21. Therapeutic progress in relapsed/refractory multiple myeloma.
Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
[TBL] [Abstract][Full Text] [Related]
22. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B; Rodriguez C; Usmani SZ
Drugs; 2022 Apr; 82(6):613-631. PubMed ID: 35412114
[TBL] [Abstract][Full Text] [Related]
23. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
24. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
Costa LJ; Rodriguez-Otero P
Adv Ther; 2024 Apr; ():. PubMed ID: 38642197
[TBL] [Abstract][Full Text] [Related]
25. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.
St Martin Y; Franz JK; Agha ME; Lazarus HM
Blood Rev; 2023 Jul; 60():101095. PubMed ID: 37173224
[TBL] [Abstract][Full Text] [Related]
26. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
27. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
28. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
29. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
30. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
31. "Off-the-shelf" immunotherapies for multiple myeloma.
Mohammed T; Mailankody S
Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
33. Cellular therapy for multiple myeloma: what's now and what's next.
Rodriguez-Otero P; San-Miguel JF
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):180-189. PubMed ID: 36485132
[TBL] [Abstract][Full Text] [Related]
34. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
35. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
36. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
37. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
38. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.
George LL; Deshpande SR; Cortese MJ; Kendall EK; Chattaraj A; Shah Z; Zhao J; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):741-751. PubMed ID: 34253497
[TBL] [Abstract][Full Text] [Related]
39. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
[TBL] [Abstract][Full Text] [Related]
40. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]